American Century Companies Inc. Has $523.46 Million Stock Holdings in Kenvue Inc. $KVUE

Key Points

• American Century Companies Inc. increased its stake in Kenvue Inc. by 15.7% during Q1, acquiring an additional 2,961,716 shares for a total ownership of about 21.83 million shares valued at $523.46 million.
• Kenvue recently increased its quarterly dividend from $0.21 to $0.2075, representing a dividend yield of 3.9% and a payout ratio of 112.16%.
• Analysts have generally lowered their price targets for Kenvue, with the current consensus target price set at $24.38 and a majority rating of "Hold."

American Century Companies Inc. increased its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 15.7% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 21,828,854 shares of the company's stock after acquiring an additional 2,961,716 shares during the period. American Century Companies Inc. owned approximately 1.14% of Kenvue worth $523,456,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of KVUE. Cambridge Investment Research Advisors Inc. raised its position in shares of Kenvue by 4.0% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company's stock valued at $2,545,000 after purchasing an additional 4,034 shares in the last quarter. IFP Advisors Inc grew its stake in Kenvue by 25.3% during the 1st quarter. IFP Advisors Inc now owns 15,278 shares of the company's stock worth $369,000 after buying an additional 3,081 shares during the last quarter. Starboard Value LP bought a new position in Kenvue during the 4th quarter worth $467,864,000. Kingswood Wealth Advisors LLC bought a new position in shares of Kenvue in the first quarter worth $413,000. Finally, Cooper Investors PTY Ltd. grew its stake in shares of Kenvue by 39.7% in the first quarter. Cooper Investors PTY Ltd. now owns 858,076 shares of the company's stock worth $20,577,000 after purchasing an additional 244,043 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Performance

NYSE:KVUE traded up $0.3850 on Tuesday, hitting $21.4850. The company's stock had a trading volume of 12,457,149 shares, compared to its average volume of 17,533,434. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The stock has a fifty day moving average of $21.54 and a two-hundred day moving average of $22.43. The firm has a market capitalization of $41.23 billion, a P/E ratio of 29.03, a price-to-earnings-growth ratio of 3.05 and a beta of 0.83. Kenvue Inc. has a one year low of $19.75 and a one year high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The company had revenue of $3.84 billion for the quarter, compared to the consensus estimate of $3.94 billion. During the same quarter in the prior year, the business earned $0.32 earnings per share. The firm's revenue for the quarter was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th will be given a $0.2075 dividend. The ex-dividend date of this dividend is Wednesday, August 13th. This is a positive change from Kenvue's previous quarterly dividend of $0.21. This represents a $0.83 annualized dividend and a dividend yield of 3.9%. Kenvue's dividend payout ratio (DPR) is currently 112.16%.

Analysts Set New Price Targets

KVUE has been the topic of a number of research analyst reports. Royal Bank Of Canada lowered their target price on Kenvue from $24.00 to $22.00 and set a "sector perform" rating on the stock in a report on Friday, August 8th. Citigroup dropped their target price on Kenvue from $24.50 to $22.00 and set a "neutral" rating for the company in a research report on Tuesday, July 15th. UBS Group decreased their price objective on Kenvue from $25.00 to $23.00 and set a "neutral" rating for the company in a research note on Thursday, July 17th. JPMorgan Chase & Co. decreased their target price on Kenvue from $27.00 to $26.00 and set an "overweight" rating for the company in a research note on Friday, July 25th. Finally, Bank of America cut their price target on Kenvue from $27.00 to $25.00 and set a "buy" rating on the stock in a report on Tuesday, July 15th. Five analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $24.38.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.